Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01735201 · ClinicalTrials.gov registry record · Phase 2
AGN-199201 for the Treatment of Erythema With Rosacea
A Phase 2 study of Rosacea and Erythema, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 357
- Enrollment target
- 1
- Study location
NCT01735201 is a Phase 2 study of Rosacea and Erythema that has completed, run by Allergan. The registered enrollment target is 357 participants, above the 228-participant average among 23 other Rosacea trials with a reported enrollment target (57% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01735201, a Phase 2 study of Rosacea and Erythema, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 357 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.
Interventions
- DRUG AGN-199201 Vehicle
- DRUG AGN-199201 Dose A
- DRUG AGN-199201 Dose B
- DRUG AGN-199201 Dose C
Study Locations (1)
Texas
- - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01735201
The ClinicalTrials.gov registry entry for NCT01735201 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 357 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 228-participant average among 23 other Rosacea trials with a reported enrollment target (57% higher). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Rosacea appearing as the primary indexed condition, and to 4 interventions - of which AGN-199201 Vehicle is the first listed.
NCT01735201 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01735201 about?
NCT01735201 is a clinical study titled "AGN-199201 for the Treatment of Erythema With Rosacea". This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.
What is the current status of trial NCT01735201?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 357 participants. The study started on 2012-12. Estimated completion is 2013-06.
What conditions does trial NCT01735201 study?
This clinical trial studies the following conditions: Rosacea, Erythema.
What interventions are being tested in trial NCT01735201?
The interventions under investigation include: AGN-199201 Vehicle (DRUG), AGN-199201 Dose A (DRUG), AGN-199201 Dose B (DRUG), AGN-199201 Dose C (DRUG).
Who is sponsoring clinical trial NCT01735201?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01735201 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
-
Rosacea and Ivermectin
COMPLETED · Phase 2
-
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 2
-
A Study of DER 45-EV Gel to Treat Rosacea
COMPLETED · Phase 2
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.